POST-COVID: EFFICACY AND SAFETY OF THIOTRIAZOLINE

Аннотация

The use of Thiotriazoline at the outpatient stage in patients with past COVID-19 infection significantly reduces cell damage with a decrease in LDH levels in the main group from 362.5±192.9 to 221.2±98.8 U/l against the dynamics from 385.9 ±210.1 to 269.0±142.9 U/l in the control group, p=0.02, reduce ALT in the main group for a month of therapy from 69.7±35.6 U/l to 30.8± 15.5 U/l compared with the control group (from 63.7±52.7 U/l to 57.4±44.7 U/l, p=0.002). The clinical efficacy of Thiotriazoline in patients who predominantly had pneumonia against the background of COVID-19 infection was manifested in an improvement in the integral indicators of their quality of life over a 30-day follow-up period. Significant changes were registered in achieving a higher level of health both in the analysis of the integral indicator of physical health (IPH) - 58.1±17.7 points versus 50.2±24.9 points in the control group, and in the analysis of the integral indicator of mental health (IMH) - 70.9±16.4 points in the main group versus 51.4±21.7 points in the control group, respectively, p=0.003, in the absence of complications or side effects of the drug.